Illumina, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ILMN research report →
Range $200 – $305
Price Chart
About the company
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains.
- CEO
- Jacob Thaysen
- IPO
- 2000
- Employees
- 8,600
- HQ
- San Diego, CA, US
AI snapshot
Six angles, distilled from the data.
ILMN remains in a larger recovery phase, but the stock is still below its 200-day average after a strong run from the 52-week low. That leaves the setup constructive yet unfinished, with overhead supply still visible well below the 52-week high.
Street sentiment is constructive: the consensus sits at Buy with an average target of 252.73, above the last close. Recent moves have been mostly target raises, even as a few firms trimmed ratings to neutral, showing higher valuation expectations but less unanimity.
The earnings profile is strong, with ILMN beating EPS in 7 of the last 8 quarters and the latest quarter topping estimates by 5.9%. Next-year EPS is modeled at 6.1827 versus 5.81 TTM, so shareholders should watch whether revenue growth and margin discipline keep supporting that path.
Recent insider activity points to heavy net selling, led by director Keith A. Meister across multiple trades in November. With 15 sales and no buys, the pattern looks like sustained distribution rather than opportunistic accumulation.
Profitability remains solid, with gross margin at 67.7% and net margin at 19.72%. Growth is positive but not explosive: revenue rose 4.2% year over year and earnings grew 45.9%, while free cash flow reached $1.227 billion in 2025.
ILMN stands out as a high-margin life sciences tools name with strong cash generation and premium profitability versus many diagnostics peers. The valuation is rich at 41.16 times earnings, so the market is already paying for continued execution.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.15B
- P/E
- 35.03
- Fwd P/E
- 35.58
- PEG
- 1.11
- P/S
- 6.87
- P/B
- 9.91
- EV/EBITDA
- 23.43
- Div Yield
- 0.00%
- Gross Margin
- 67.87%
- Op Margin
- 21.15%
- Net Margin
- 19.72%
- ROE
- 31.45%
- ROIC
- 14.15%
Latest fiscal year · YoY change
- Revenue
- $4.34B-0.7%
- Gross Profit
- $2.87B+0.3%
- Op Income
- $807.00M
- Net Income
- $850.00M+169.5%
- EPS
- $5.47+171.1%
- OCF Growth
- +28.9%
- FCF Growth
- +31.3%
- 52W High
- $309.35
- 52W Low
- $112.65
- 50D MA
- $248.54
- 200D MA
- $180.79
- Beta
- 1.45
- RSI (14)
- 34
- Avg Volume
- 2.82M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Illumina beat Q3 expectations, with strong clinical sequencing demand and NovaSeq X placements driving a raise to full-year revenue, margin, and EPS guidance.· October 29, 2026
- Q3 revenue was $1.17 billion, up 4.7% year over year on a rest-of-world organic basis; diluted EPS was $1.44, up 7% year over year.
- Gross margin was 69.4% and operating margin was 25%, both ahead of expectations; operating margin was 100 basis points above guidance.
- Sequencing consumables revenue rose to $792 million, up 6% year over year, led by high-throughput volume and an expanding NovaSeq X installed base.
- Illumina placed over 80 NovaSeq X instruments in the quarter, bringing the last four quarters to about 360 placements.
- Management raised full-year 2026 guidance for revenue, operating margin, and EPS, and said it remains on track for long-range financial targets.
Illumina reported Q3 2026 revenue of $1.17 billion, up 4.7% year over year on a rest-of-world organic basis, with currency and acquisitions contributing just under three percentage points to reported growth. Sequencing consumables revenue was $792 million, up 6% year over year and up 5% on an organic rest-of-world basis; sequencing instruments revenue was $106 million, down 2% year over year on a rest-of-world organic basis; sequencing service and other revenue was $158 million, up 8% on a rest-of-world organic basis; and microarrays and other revenue was $110 million, up 2% on a rest-of-world organic basis. Gross margin was 69.4%, up 20 basis points year over year, operating margin was 25%, and diluted EPS was $1.44, up 7% year over year. For cash flow, operating cash flow was $419 million and free cash flow was $378 million. For 2026, management raised revenue guidance to $4.64 billion to $4.66 billion, expects operating margin of approximately 23.6% at the high end of the prior range, and now guides to diluted EPS of $5.40 to $5.45. For Q4 2026, it expects revenue of $1.22 billion to $1.24 billion, rest-of-world organic growth of approximately 4.5%, EPS of $1.51 to $1.56, and operating margin of approximately 25%.
Jacob Thaysen said the quarter showed Illumina’s strategy is working, pointing to strong clinical sequencing demand, elevated NovaSeq X placements, and momentum in software and AI-enabled data offerings. He emphasized that the Billion Cell Atlas and BioInsight are designed to help customers generate standardized, reproducible datasets for AI biology, target validation, and drug discovery. His tone was confident and upbeat, but he also repeatedly framed 2027 as a topic for the next call rather than giving detailed forward guidance now.
Ankur Dhingra focused on the beat versus guidance and the quality of the revenue mix. He said operating margin of 25% was 100 basis points above guidance, gross margin was 69.4%, and EPS of $1.44 was above the high end of the range; he also highlighted $419 million of operating cash flow and $378 million of free cash flow. On capital allocation, he said Illumina repurchased $9 million of stock in the quarter, had about $1.8 billion remaining under share repurchase authorization, and ended with about $1.34 billion in cash and equivalents and short-term investments versus $1.79 billion in total debt.
Analysts focused on whether strong clinical consumable growth is sustainable, whether NovaSeq X demand reflects pull-forward, what 2027 could look like, and how pricing and discounts might evolve as the X transition matures. Management said there was no indication of pull-forward, that clinical growth should stay in the mid-teens for 2026, and that the Q4 consumables guide was being raised because of strong placements and demand. They also said the X transition is near completion in research and applied and approaching 80% to 85% conversion in clinical, which should reduce pricing headwinds in 2027 versus 2026; on China, they said they remain committed to the market but are still assessing the impact of recent regulatory developments.
The bullish case from this call is that core demand remains healthy, especially in clinical, where management said growth was 14% to 15% in Q3 and should remain mid-teens for the full year. NovaSeq X placements stayed strong at over 80 units in the quarter, suggesting more consumables revenue ahead as the installed base expands. Management also described BioInsight, the Billion Cell Atlas, and multi-omics as additional growth drivers that could start to show up more clearly in 2027 and beyond.
The main risks discussed were continued weakness in research and applied sequencing consumables, which declined 6% in the quarter and are still expected to fall mid to high single digits in 2026. China remains an uncertainty because management is still assessing the impact of regulatory issues, even though they said they are committed to the market. Several analysts also pressed on whether NovaSeq X pricing, discounts, and the maturity of the transition could eventually slow growth, especially as the company moves into 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 151.20M
- Float Shares
- 150.68M
of shares held by institutions
974 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ILMN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Oct 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 10, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 9, 25 | Filing → |
| Thomas KeanHouse · NJ07 | Buy | Apr 1, 25 | Filing → |
| Thomas KeanHouse · NJ07 | Buy | Apr 1, 25 | Filing → |
| Michael C. BurgessHouse · TX26 | Sell | Aug 30, 24 | Filing → |
| Michael C. BurgessHouse · TX26 | Sell | Sep 3, 24 | Filing → |
| Thomas KeanHouse · NJ07 | Buy | Apr 19, 24 | Filing → |
| Michael C. BurgessHouse · TX26 | Sell | Mar 11, 24 | Filing → |
| Michael C. BurgessHouse · TX26 | Sell | Mar 11, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 16.19M | ▲ 11.66M |
| Blackrock, Inc. | 15.85M | ▼ 3.34M |
| Vanguard Group Inc | 14.36M | ▼ 272.50K |
| Vanguard Capital Management LLC | 9.89M | ▲ 3.30M |
| Capital World Investors | 9.88M | ▼ 5.54M |
| State Street Corp | 7.19M | ▲ 681.32K |
| Vanguard Portfolio Management LLC | 6.34M | ▼ 283.59K |
| Wcm Investment Management, LLC | 5.73M | ▼ 473.13K |
| Jpmorgan Chase & Co | 4.94M | ▲ 3.76M |
| Geode Capital Management, LLC | 4.22M | ▲ 1.27M |
| Primecap Management Co | 3.49M | ▼ 23.67K |
| Aqr Capital Management LLC | 3.06M | ▼ 482.71K |
Held by 1,803 ETFs
Biggest fund positions in ILMN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Meister Keith A. | sell | 6,024 |
| Nov 9, 26 | Meister Keith A. | sell | 12,202 |
| Nov 9, 26 | Meister Keith A. | sell | 16,383 |
| Nov 9, 26 | Meister Keith A. | sell | 55,532 |
| Nov 9, 26 | Meister Keith A. | sell | 23,528 |
| Nov 9, 26 | Meister Keith A. | sell | 4,898 |
| Nov 10, 26 | Meister Keith A. | sell | 13,828 |
| Nov 10, 26 | Meister Keith A. | sell | 20,693 |
| Nov 10, 26 | Meister Keith A. | sell | 19,914 |
| Nov 10, 26 | Meister Keith A. | sell | 1,177 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ILMN coverage
Recent articles, reports, and earnings notes.

Illumina (ILMN): Clinical Sequencing Rebuild Gains Traction
Illumina is rebuilding growth around clinical sequencing, NovaSeq X consumables, and multi-omics, but valuation keeps the stock in Hold territory. Q3 results and raised guidance show momentum, yet the shares already price in much of the recovery.

Illumina, Inc. (ILMN) falls 13% After Q3 Earnings
Illumina, Inc. (ILMN) falls after-hours after its Q3 report, even as the company raised full-year guidance. Investors are focusing on a slight revenue miss, China-related pressure, and a premium valuation that leaves little room for disappointment.

Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss
Illumina, Inc. (ILMN) falls sharply after reporting third-quarter results that beat adjusted profit estimates but missed on revenue. The company also raised full-year guidance, yet investors focused on the sales shortfall and the stock’s extended-hours drop.
Want a deeper read on ILMN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
RPRX vs. ILMN: Which Stock Should Value Investors Buy Now?
zacks.com · Nov 20
Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
prnewswire.com · Nov 19
Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive?
zacks.com · Nov 19
Diamond Hill Mid Cap Strategy Q3 2026 Portfolio Review
seekingalpha.com · Nov 18
Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Illumina Sees Strong Clinical Demand, but Research Recovery Remains in Question
marketbeat.com · Nov 17
Thrivent Mid Cap Stock Fund Q3 2026 Performance Review
seekingalpha.com · Nov 16
NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.
defenseworld.net · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice